Business Wire

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced the advancement of two key strategic ...
Nasdaq

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroergotamine ...
Nasdaq

Amneal Pharmaceuticals Receives FDA Approval for Brekiya®, First DHE Autoinjector for Self-Administration in Migraine and Cluster Headache Treatment

Amneal Pharmaceuticals has received FDA approval for Brekiya®, the first and only dihydroergotamine (DHE) autoinjector designed for patients to self-administer for acute migraine and cluster headaches ...
Reuters

Amneal asks court to block Colorado's free allergy pen program

Sept 23 (Reuters) - Amneal Pharmaceuticals (AMRX.O), opens new tab has sued Colorado in an effort to block a state law requiring it to provide free generic EpiPens to pharmacies. In a complaint, opens ...